US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

703.16

+13.581.97%

Number of Gainers:47

Number of Losers:95

Number of Flat:11

PE:- -

High:707.24

Open:689.67

Low:689.64

Close:689.58

Volume:499.41M

Turnover:18.06B

Market Cap:485.23B

Float Cap:369.77B

Loading ...

Cardiol Therapeutics to Showcase Cardiac Drug Pipeline at H.C. Wainwright Conference

ProQR Therapeutics doses first participant in AX-0811 clinical trial

IN8bio Appoints Oxana Polyakova, Ph.d., as Senior Vice President of Research & Development

THOMSON REUTERS

Press Release: IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

Piper Sandler Initiates Oklo at Overweight

MT Newswires Live

Robinhood Stock Gains as Mizuho Says HOOD Could See Another ‘SpaceX-Like Trading Surge’

Analysts Have Conflicting Sentiments on These Consumer Cyclical Companies: FIGS (FIGS), Casey’s General (CASY) and Royal Caribbean (RCL)

LifeStance Health Falls as PE Backers to Carve Stakes

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

Core & Main's Q2 Sales Slightly Beat, Adjusted EPS Tops Estimates

Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates

MT Newswires Live

Core & Main Q2 Sales USD 2,145 Million Vs. IBES Estimate USD 2,136 Million

Core & Main Inc Fy2026 Shr View $2.89, REV View $7.68 Bln

THOMSON REUTERS

Core & Main Q2 Adjusted EPS USD 0.94 VS. Ibes Estimate USD 0.92

THOMSON REUTERS

Core & Main Q2 Net Income USD 150 Million

THOMSON REUTERS

Core & Main - Reaffirms Full-Year Fiscal 2026 Outlook Issued in March 2026

THOMSON REUTERS

Core & Main FY26 Q2 Net Income Climbs 6.4% to $150 Million; Net Sales Rise 2.5% to $2.15 Billion

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

LifeStance announces 22.25M share offering of common stock for holders

Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/BK4539/news?page=30"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":703.16394,"timestamp":1789761599999,"preClose":689.5794,"halted":0,"volume":499414856,"delay":0,"changeRate":0.0197,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":13.584534,"latestTime":"09-18 16:00:00 EDT","open":689.67395,"high":707.24146,"low":689.6394,"amount":18064922513.199635,"amplitude":0.025526,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.238276,"peRate":114.534565,"turnoverRate":0.039081,"increases":47,"decrements":95,"flats":8,"marketCap":485234363991.625,"floatMarketCap":369774303250.875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":707.24146,"amplitude":0.025526,"preClose":689.5794,"low":689.6394,"pbRate":"5.238276","latestPrice":703.16394,"volume":499414856,"delay":0,"open":689.67395,"prevYearClose":881.5255,"prevWeekClose":693.0266,"prevMonthClose":701.0681,"prevQuarterClose":742.922,"fiveDayClose":693.0266,"twentyDayClose":673.0297,"sixtyDayClose":707.541,"secType":"PLATE","market":"US","turnoverRate":0.039081,"peRate":114.534565,"marketCap":485234363991.625,"floatMarketCap":369774303250.875,"timestamp":1789761599999,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":47,"down":95,"flat":11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:30,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666051538","title":"Cardiol Therapeutics to Showcase Cardiac Drug Pipeline at H.C. Wainwright Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666051538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666051538?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:18","pubTimestamp":1788956307,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Cardiol Therapeutics ( ($TSE:CRDL) ). Cardiol Therapeutics said it will take part in a fireside chat at the H.C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-to-showcase-cardiac-drug-pipeline-at-h-c-wainwright-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-to-showcase-cardiac-drug-pipeline-at-h-c-wainwright-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538091","title":"ProQR Therapeutics doses first participant in AX-0811 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538091?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:15","pubTimestamp":1788956125,"startTime":"0","endTime":"0","summary":"ProQR Therapeutics (PRQR) announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. Publi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","LENZ","LU1861217088.USD","AX","MEDX","BK4211","LU1861220207.SGD","IDNA","PRQR","NVIB","BK4139","BK4007","LU2360107671.USD","BK4195","GDOC","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666053885","title":"IN8bio Appoints Oxana Polyakova, Ph.d., as Senior Vice President of Research & Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2666053885","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666053885?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:00","pubTimestamp":1788955200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUAD99RX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","INAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666383835","title":"Press Release: IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2666383835","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666383835?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:00","pubTimestamp":1788955200,"startTime":"0","endTime":"0","summary":"Renowned <GAMMA> T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bioAppointment strengthens IN8bio's leadership and domain expertise as the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","INAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580049","title":"Piper Sandler Initiates Oklo at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580049","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580049?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:59","pubTimestamp":1788955190,"startTime":"0","endTime":"0","summary":"Oklo (OKLO) has an average rating of overweight and mean price target of $75.03, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4606","BK4539","URA","BK4081","NLR","OKLO","URAN","OKLC","OKLS","OKLL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666385665","title":"Robinhood Stock Gains as Mizuho Says HOOD Could See Another ‘SpaceX-Like Trading Surge’","url":"https://stock-news.laohu8.com/highlight/detail?id=2666385665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666385665?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:59","pubTimestamp":1788955174,"startTime":"0","endTime":"0","summary":"Robinhood Markets ($HOOD) stock is up about 2% in pre-market trading on Wednesday after falling 3.91% in the previous session. The stock is getting...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/robinhood-stock-hood-is-rising-today-how-much-upside-do-analysts-see?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/robinhood-stock-hood-is-rising-today-how-much-upside-do-analysts-see?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HODU","HOOG","ROBN","BK4539","HOOC","BK4547","HOOY","CRPT","BK4127","IAI","BPAY","HOOI","HOOX","LU1861558580.USD","HOOZ","HOYY","LU1861559042.SGD","FINX","BLCK","HOII","HOOD","HOOW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580055","title":"Analysts Have Conflicting Sentiments on These Consumer Cyclical Companies: FIGS (FIGS), Casey’s General (CASY) and Royal Caribbean (RCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580055","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580055?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:50","pubTimestamp":1788954627,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on FIGS (FIGS), Casey’s General (CASY) and Royal Caribbean (R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-consumer-cyclical-companies-figs-figs-caseys-general-casy-and-royal-caribbean-rcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-consumer-cyclical-companies-figs-figs-caseys-general-casy-and-royal-caribbean-rcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FXG","BK4202","BK4198","BK4142","BK4535","BK4561","BK4588","LU1670628061.USD","BK4585","RCL","LU0109391861.USD","LU0672654240.SGD","BK4517","LU0266013472.USD","LU1878469433.USD","IE0009354923.USD","WNDR","BK4566","FIGS","BK4113","LU0320765059.SGD","LU0708995401.HKD","LU1267930730.SGD","CASY","BK4539","LU1670627923.USD","LU1366192091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666416580","title":"LifeStance Health Falls as PE Backers to Carve Stakes","url":"https://stock-news.laohu8.com/highlight/detail?id=2666416580","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666416580?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:48","pubTimestamp":1788954490,"startTime":"0","endTime":"0","summary":"BUZZ-LifeStance Health falls as PE backers to carve stakesUpdates** Shares of outpatient mental healthcare provider LifeStance HealthLFST.Odown 2.7% to $12.45 premarket on Weds after launching secondary offering** Scottsdale, Arizona-based LFST says certain stockholders to part with 22.25 mln shares** In addition, LFST to repurchase 2 mln of offering shares from the underwriter Barclays** Private equity firms TPG CapitalTPG.Oand Summit Partners looking to sell ~18.41 mln shares and ~3.84 mln shares, respectively, per the prospectus** LFST has ~382.1 mln shares outstanding** Through Tues, stock up 67% over the past three months and 82% YTD** 9 of 12 analysts rate the stock \"strong buy\" or \"buy\", 3 \"hold\"; median PT $13","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL6N4510UI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048578792.EUR","AAUM","LU1023061473.USD","PRVT","LU0345770308.USD","LU1023061713.HKD","LU0106831901.USD","BK4539","LU0345770993.USD","LU0171281750.USD","LU0997586606.USD","LU1035777561.USD","BK4135","IE00B3T34201.USD","LU0047473722.EUR","PSP","BK4196","LU0345777147.USD","BK4535","LU0575583348.USD","LU0550127509.SGD","LU0047473722.SGD","LU2646069778.SGD","LFST","BARC.UK","LU0987226296.USD","LU1668664300.SGD","LU1064927863.SGD","LU1791807156.HKD","BK5152","TPG","LU0345777659.USD","LU1015430645.USD","FMED","LU0964806797.USD","LU0161305163.EUR","LU1078025761.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666358001","title":"Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2666358001","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666358001?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:45","pubTimestamp":1788954300,"startTime":"0","endTime":"0","summary":"- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evalu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358540/0/en/serina-therapeutics-reports-cohort-1-observations-from-ser-252-registrational-study-in-advanced-parkinson-s-disease-and-advances-to-cohort-2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","LU2089985449.USD","IE0031619046.USD","IE00B19Z4B17.USD","LENZ","BK4007","BK4539","LU1815336091.USD","IE00B66KJ199.SGD","AEIS","BK4139","LU0757428866.USD","SMC","LU0274383776.USD","LU2931357623.SGD","BK4157","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666989580","title":"Core & Main's Q2 Sales Slightly Beat, Adjusted EPS Tops Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2666989580","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666989580?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:39","pubTimestamp":1788953967,"startTime":"0","endTime":"0","summary":"Core & Main's Q2 sales slightly beat, adjusted EPS tops estimatesOverviewUS specialty distributor's fiscal Q2 net sales grew 2.5%, slightly beating analyst expectationsAdjusted EPS for fiscal Q2 beat ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL1N4510F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125910179.SGD","LU1620156213.USD","BK4104","LU2089279066.USD","BK4539","LU1721427968.SGD","EVI","LU1620156130.USD","LU1543694498.USD","BK4102","LU2413666004.HKD","LU1165135440.EUR","LU2413665964.HKD","IE0009354923.USD","LU1923621640.USD","CNM","LU1596574779.USD","UNFI","LU2229751404.USD","LU2125910336.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666958050","title":"Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates","url":"https://stock-news.laohu8.com/highlight/detail?id=2666958050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666958050?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:33","pubTimestamp":1788953580,"startTime":"0","endTime":"0","summary":"Schrodinger (SDGR), along with New Enterprise Associates and RA Capital Management, established a new biotechnology company named Tectora Therapeutics, according to a Wednesday statement.Concurrently,","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","BK4007","BK4211","BK4588","BK4167","EFSC","SDGR","LENZ","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666258054","title":"Core & Main Q2 Sales USD 2,145 Million Vs. IBES Estimate USD 2,136 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666258054","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666258054?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:32","pubTimestamp":1788953520,"startTime":"0","endTime":"0","summary":"BRIEF-Core & Main Q2 Sales USD 2,145 Million Vs. IBES Estimate USD 2,136 MillionSep 09 (Reuters) - Core & Main Q2 adjusted EBITDA USD 274 million vs. IBES estimate USD 280.7 million.Q2 adjusted EPS USD 0.94 vs. IBES estimate USD 0.92Q2 EPS USD 0.77Q2 net income USD 150 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nPLXMXWSN4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNM","IE0009354923.USD","LU1620156130.USD","BK4104","LU1721427968.SGD","LU2089279066.USD","LU2125910179.SGD","LU1923621640.USD","LU2229751404.USD","LU2413665964.HKD","LU2413666004.HKD","BK4539","LU1543694498.USD","LU1620156213.USD","LU1596574779.USD","LU2125910336.SGD","LU1165135440.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580567","title":"Core & Main Inc Fy2026 Shr View $2.89, REV View $7.68 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580567","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580567?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:31","pubTimestamp":1788953461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nPLXMXWSN4:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1620156213.USD","LU1923621640.USD","LU1721427968.SGD","LU1543694498.USD","LU1620156130.USD","LU2125910179.SGD","LU2413665964.HKD","IE0009354923.USD","LU2125910336.SGD","LU1165135440.EUR","LU1596574779.USD","BK4539","BK4104","LU2089279066.USD","LU2229751404.USD","LU2413666004.HKD","CNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580325","title":"Core & Main Q2 Adjusted EPS USD 0.94 VS. Ibes Estimate USD 0.92","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580325?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:31","pubTimestamp":1788953461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nPLXMXWSN4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","LU1165135440.EUR","LU1620156213.USD","LU1721427968.SGD","BK4104","LU2413665964.HKD","IE0009354923.USD","LU1596574779.USD","LU1923621640.USD","LU2125910179.SGD","LU2125910336.SGD","LU2413666004.HKD","CNM","LU1620156130.USD","LU2089279066.USD","LU1543694498.USD","LU2229751404.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580320","title":"Core & Main Q2 Net Income USD 150 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580320?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:31","pubTimestamp":1788953461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nPLXMXWSN4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2089279066.USD","CNM","LU2413665964.HKD","LU1923621640.USD","LU1543694498.USD","LU1596574779.USD","LU2125910179.SGD","LU2125910336.SGD","LU2229751404.USD","LU1620156213.USD","LU1721427968.SGD","LU2413666004.HKD","IE0009354923.USD","BK4539","LU1165135440.EUR","BK4104","LU1620156130.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309580","title":"Core & Main - Reaffirms Full-Year Fiscal 2026 Outlook Issued in March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309580?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:31","pubTimestamp":1788953461,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nPLXMXWSN4:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1543694498.USD","BK4104","LU2125910179.SGD","LU1620156130.USD","IE0009354923.USD","LU1165135440.EUR","LU1620156213.USD","LU1721427968.SGD","LU1596574779.USD","LU1923621640.USD","LU2089279066.USD","LU2125910336.SGD","LU2229751404.USD","LU2413665964.HKD","BK4539","LU2413666004.HKD","CNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580537","title":"Core & Main FY26 Q2 Net Income Climbs 6.4% to $150 Million; Net Sales Rise 2.5% to $2.15 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580537","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580537?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:30","pubTimestamp":1788953456,"startTime":"0","endTime":"0","summary":"Core & Main FY26 Q2 net income climbs 6.4% to $150 million; net sales rise 2.5% to $2.15 billionCore & Main posted fiscal 2026 Q2 net sales up 2.5% to $2.15 billion versus the prior-year quarter.GAAP ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL6TL72h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNM","LU2125910179.SGD","LU2089279066.USD","LU2413665964.HKD","LU1721427968.SGD","LU2413666004.HKD","LU2229751404.USD","IE0009354923.USD","LU1620156213.USD","LU1543694498.USD","LU1620156130.USD","LU1165135440.EUR","LU2125910336.SGD","BK4104","LU1923621640.USD","BK4539","LU1596574779.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666800915","title":"Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2666800915","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666800915?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:30","pubTimestamp":1788953400,"startTime":"0","endTime":"0","summary":"CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358524/0/en/context-therapeutics-announces-first-patient-dosed-in-phase-1-trial-of-ct-202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666872955","title":"LifeStance announces 22.25M share offering of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2666872955","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666872955?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:15","pubTimestamp":1788952541,"startTime":"0","endTime":"0","summary":"LifeStance (LFST) Health Group announced that pursuant to a shelf registration statement filed with the SEC, certain stockholders of the company in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lifestance-announces-22-25m-share-offering-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lifestance-announces-22-25m-share-offering-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4539","LFST","BK4535","FMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666796587","title":"Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel","url":"https://stock-news.laohu8.com/highlight/detail?id=2666796587","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666796587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:15","pubTimestamp":1788952531,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics (AUTL) announced that the FDA has granted regenerative medicine advanced therapy, or RMAT, designation to obecabtagene autoleu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-granted-rmat-designation-for-obecabtagene-autoleucel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-granted-rmat-designation-for-obecabtagene-autoleucel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4585","BK4139","BK4007","LABU","AUTL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":40,"pageCount":30,"totalSize":782,"code":"91000000","status":"200"}]}}